Sunday , July 5 2020
Home / 2017 / Investra-24hs USFDA warning Letter 12/28/17

Investra-24hs USFDA warning Letter 12/28/17

Investra-24hs USFDA warning Letter

WARNING LETTER

The United States (U.S.) Food and Drug Administration (FDA) recently reviewed your websites (listed at the bottom of this letter) and determined that they offer products for sale in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). More specifically, the websites listed below offer unapproved new drugs and misbranded drugs for sale in violation of sections 301(a), 301(d), 503(b), and 505(a) of the FD&C Act [21 U.S.C. §§ 331(a), 331(d), 353(b), and 355(a)]. FDA requests that you immediately cease marketing violative drug products to U.S. consumers.
 (Notice of Unlawful Sale of Unapproved and Misbranded Drug Products to United States Consumers over the Internet)
 Image result for usfda warning letter

About Pharmaceutical Guidanace

Mr. Shiv Kumar is the Author and founder of pharmaceutical guidance, he is a pharmaceutical Professional from India having more than 14 years of rich experience in pharmaceutical field. During his career, he work in quality assurance department with multinational company’s i.e Zydus Cadila Ltd, Unichem Laboratories Ltd, Indoco remedies Ltd, Panacea Biotec Ltd, Nectar life Science Ltd. During his experience, he face may regulatory Audit i.e. USFDA, MHRA, ANVISA, MCC, TGA, EU –GMP, WHO –Geneva, ISO 9001-2008 and many ROW Regularities Audit i.e.Uganda,Kenya, Tanzania, Zimbabwe. He is currently leading a regulatory pharmaceutical company as a head Quality. You can join him by Email, Facebook, Google+, Twitter and YouTube

Check Also

USFDA Warning Letter for Alkermes, Inc.

Alkermes, Inc. MARCS-CMS 597260 — December 02, 2019 For Warning Letter Click Here –   Matters …